Thoraxonkologie Heidelberg – Neoplasms

Clinical research at Thoraxklinik Heidelberg gGmbH is strongly focused on cancer, especially lung cancer and related thoracic tumors. Studies are examining whether newer treatment combinations can improve survival, slow disease progression, and offer better options for patients with advanced or previously treated disease.

  • Small cell lung cancer and extensive-stage small-cell lung cancer
  • Non-Small Cell Lung Cancer (NSCLC), including metastatic and c-Met overexpressing forms
  • Pleural mesothelioma, neuroendocrine carcinoma, and other aggressive thoracic cancers

These trials are mainly testing new therapies and comparing them with current standards of care to find more effective approaches for hard-to-treat thoracic malignancies.

Respiratory Tract Diseases

The site also supports important studies in respiratory disease, with a particular emphasis on chronic and progressive lung conditions. Research here is aimed at improving breathing capacity, preserving lung function, and easing the long-term impact of serious pulmonary illness.

  • Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
  • Pulmonary arterial hypertension and related forms of PAH
  • Trials assessing symptom control, exercise tolerance, and disease progression

At this Heidelberg hospital, the goal is to evaluate new treatments that may better manage debilitating lung diseases and improve day-to-day function for patients.

Cardiovascular Diseases and Pulmonary Vascular Research

Another key area of research involves pulmonary vascular disease, bridging cardiovascular and respiratory medicine. The studies are centered on pulmonary arterial hypertension, where investigators are looking for therapies that can reduce disease burden and improve physical capacity.

  • Pulmonary arterial hypertension in multiple patient groups
  • Measures of exercise ability and vascular resistance
  • Evaluation of treatment effectiveness in a chronic, high-impact condition

These trials reflect a broader effort to advance care for patients with serious cardiopulmonary disorders through better disease control and functional outcomes.